Skip to main content

Diabetes Typ 2

Gliflozin verbessert Urin-Metabolom auch bei nierengesunden Diabetikern

This is a preview of subscription content, access via your institution.

Literatur:

  1. 1.

    Ferrannini E, Mark M, Mayoux E. CV-Protection in the EMPA-REG Outcome trial a "thrifty substrate" hypothesis. Diabetes Care 2016; 39(7):1108-4

  2. 2.

    Mulder S, Heerspink HJL, Darshi M, et al. Effects of dapaglifozin on urine metabolites in people with type 2 diabetes. Diabetes Obes Metab 2019; 21 (11):2422-2428

  3. 3.

    Vallon V, Gerasimova M, Rose MA, et al. SGLT2 Inhibitor empaglifozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. Am J Physiol Renal Physiol 2014;306(2): F194-F204

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Emanuel Fritschka.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Fritschka, E. Gliflozin verbessert Urin-Metabolom auch bei nierengesunden Diabetikern. Info Diabetol 15, 16–17 (2021). https://doi.org/10.1007/s15034-021-3701-5

Download citation